We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 546

U.S. Supreme Court allows application of first-sale doctrine to books published abroad
  • Shook Hardy & Bacon LLP
  • USA
  • March 21 2013

The U.S. Supreme Court has determined that a Thai student who came to the United States to study mathematics at Cornell University and earned money


Kappos to leave USPTO, confirms support for software patents
  • Shook Hardy & Bacon LLP
  • USA
  • December 6 2012

U.S. Patent and Trademark Office (USPTO) Director David Kappos reportedly plans to leave the position in January 2013


French company prevails in dispute with FDA over drug-classification ruling
  • Shook Hardy & Bacon LLP
  • USA
  • October 3 2012

A federal court in the District of Columbia has determined that the Food and Drug Administration (FDA) erred when it classified a combination drug-device product as primarily a drug, thus subjecting its French manufacturer to more burdensome regulatory requirements


Syros Pharmaceuticals raises $30 million for cancer research
  • Shook Hardy & Bacon LLP
  • USA
  • April 18 2013

Newly launched life sciences company, Syros Pharmaceuticals, has announced a $30 million Series A financing round led by company co-founders Arch


USPTO dedicates resources to Office of International Patent Cooperation
  • Shook Hardy & Bacon LLP
  • USA
  • April 17 2014

The U.S. Patent and Trademark Office (USPTO) has established a new Office of International Patent Cooperation; Mark Powell, who has worked


Texas compounder agrees to nationwide recall of all sterile products
  • Shook Hardy & Bacon LLP
  • USA
  • August 15 2013

According to the U.S. Food and Drug Administration (FDA), Cedar Park, Texas-based compounding pharmacy Specialty Compounding LLC has agreed to recall


President’s budget proposes banning “pay for delay” agreements
  • Shook Hardy & Bacon LLP
  • USA
  • April 18 2013

The pharmaceutical industry has weighed in on President Barack Obama's proposed 2014 fiscal year budget, finding much to criticize, including a


Tetragenetics Inc. receives $826 million grant for malaria vaccine
  • Shook Hardy & Bacon LLP
  • USA
  • April 18 2013

Tetragenetics Inc. has received an $826-million Phase 2 grant as well as new partnerships with two drug companies, according to a news source. The


Crop biotech company secures $14.5 million in series A financing
  • Shook Hardy & Bacon LLP
  • USA
  • April 18 2013

A private company that develops agricultural products designed to improve crop productivity has reportedly raised $14.5 million in a Series A


Cancer genetics IPO raises $6.9 million
  • Shook Hardy & Bacon LLP
  • USA
  • April 18 2013

Rutherford, New Jersey-based Cancer Genetics, Inc., an early-stage diagnostics company that develops genomic-based, oncology tests and services, has